Home  »  Business   »  Is Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) A...

Is Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) A Suitable Stock For New Investors Today?

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) shares, rose in value on Friday, 05/13/22, with the stock price up by 1.55% to the previous day’s close as strong demand from buyers drove the stock to $35.34.

Actively observing the price movement in the last trading, the stock closed the session at $34.80, falling within a range of $34.19 and $35.43. The value of beta (5-year monthly) was 0.71 whereas the PE ratio was 28.41 over 12-month period. Referring to stock’s 52-week performance, its high was $44.46, and the low was $17.56. On the whole, AMPH has fluctuated by -16.43% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.

Sponsored

With the market capitalization of Amphastar Pharmaceuticals Inc. currently standing at about $1.80 billion, investors are eagerly awaiting this quarter’s results, scheduled for Mar 14, 2022 – Mar 18, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.37, which is expected to increase to $0.31 for fiscal year $1.32 and then to about $1.49 by fiscal year 2022. Data indicates that the EPS growth is expected to be 106.20% in 2022, while the next year’s EPS growth is forecast to be 12.90%.

Analysts have estimated the company’s revenue for the quarter at $112.08 million, with a low estimate of $109 million and a high estimate of $116.39 million. According to the average forecast, sales growth in current quarter could jump up 16.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $428.96 million, representing an increase of 22.60% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that AMPH’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

The stock’s technical analysis shows that the PEG ratio is about 1.14, with the price of AMPH currently trading nearly -1.79% and -0.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.71, while the 7-day volatility ratio is showing 5.82% which for the 30-day chart, stands at 5.06%. Furthermore, Amphastar Pharmaceuticals Inc. (AMPH)’s beta value is 0.64, and its average true range (ATR) is 1.83. The company’s stock has been forecasted to trade at an average price of $38.25 over the course of the next 52 weeks, with a low of $32.00 and a high of $45.00. Based on these price targets, the low is 9.45% off current price, whereas the price has to move -27.33% to reach the yearly target high. Additionally, analysts’ median price of $38.00 is likely to be welcomed by investors because it represents a decrease of -7.53% from the current levels.

A comparison of Amphastar Pharmaceuticals Inc. (AMPH) with its peers suggests the former has fared considerably weaker in the market. AMPH showed an intraday change of 1.55% in last session, and over the past year, it grew by 76.97%%. In comparison, SCYNEXIS Inc. (SCYX) has moved higher at 10.70% on the day and was down -70.89% over the past 12 months. On the other hand, the price of Agile Therapeutics Inc. (AGRX) has fallen -1.21% on the day. The stock, however, is off -97.47% from where it was a year ago. The PE ratio stands at 28.41 for Amphastar Pharmaceuticals Inc. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) indicates that the trading volumes over the past 3 months, they’ve averaged 486.95K. According to company’s latest data on outstanding shares, there are 47.83 million shares outstanding.

Nearly 5.60% of Amphastar Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 61.60% of the company’s shares. The stock has risen by 51.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AMPH stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam